Jeff Hrkach

Senior Vice President, Technology Development at Frequency Therapeutics, Inc.

Jeff Hrkach

Jeff Hrkach

Senior Vice President, Technology Development at Frequency Therapeutics, Inc.

Overview
Career Highlights

DNIB Unwind, Inc.

RelSci Relationships

2276

Number of Boards

1

Birthday

1966

Age

54

Relationships
RelSci Relationships are individuals Jeff Hrkach likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Seer, Inc.

Relationship likelihood: Strong

Chairman, Global Treatment Sciences Network at Prostate Cancer Foundation

Relationship likelihood: Strong

Edward Mallinckrodt Junior Professor-Immunopathology at Harvard University - Harvard Medical School

Relationship likelihood: Strong

Co-Founder at Pulmatrix, Inc. (Inactive)

Relationship likelihood: Strong

Medical Director at Semafore Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chaus Professor-Urologic Oncology at Cornell University

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Chief Executive Officer & Director at Moderna, Inc.

Relationship likelihood: Strong

Paths to Jeff Hrkach
Potential Connections via
Relationship Science
You
Jeff Hrkach
Senior Vice President, Technology Development at Frequency Therapeutics, Inc.
Education
Ph.D Chemistry

Carnegie Mellon University challenges the curious and passionate to imagine and deliver work that matters. A private, global research university, Carnegie Mellon stands among the world's most renowned educational institutions, and sets its own course.With cutting-edge brain science, path-breaking performances, innovative start-ups, driverless cars, big data, big ambitions, Nobel and Turing prizes, hands-on learning, and a whole lot of robots, CMU doesn't imagine the future, they create it.

Philadelphia University was founded in 1884 as the Philadelphia Textile School in the wake of the 1876 Centennial Exposition. A group of textile manufacturers, led by Theodore Search, noticed a sizeable gap between the quality and variety of American textile products and those displayed by European mills. To address this, the group established the School to educate America’s textile workers and managers. Several years later, the School affiliated with the Pennsylvania Museum (now the Philadelphia Museum of Art) and School of Industrial Art. By 1949, PTI, which was no longer affiliated with the museum, began conducting classes at its present site in the East Falls section of Philadelphia. Throughout the 1950s, it continued to grow, and, in 1961, changed its name to Philadelphia College of Textiles & Science. The Board of Trustees voted to change the School’s name to Philadelphia University on July 13, 1999.

BS Chemistry

University of the Sciences, are building on a life sciences legacy started almost two centuries ago as Philadelphia College of Pharmacy. From treating, researching and studying diseases and cures on a molecular level to the medicines that improve the lives of people worldwide, USciences is about moving life forward. The University has launched the careers of many innovative and pioneering individuals in the field of healthcare. The University is accredited by the Commission on Higher Education of the Middle States Association of Colleges and Schools.

Career History
Senior Vice President, Technology Development
2019 - Current

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean in November 13, 2014 and is headquartered in Woburn, MA.

Head
Tenure Unconfirmed

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Co-Head Delivery Sciences
2016 - Prior

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

DNIB Unwind, Inc. raised money in a private placement transaction

Details Hidden

DNIB Unwind, Inc. raised money in a private placement transaction

Details Hidden

DNIB Unwind, Inc. raised money in a private placement transaction

Investments
Details Hidden

DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jeff Hrkach. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jeff Hrkach's profile does not indicate a business or promotional relationship of any kind between RelSci and Jeff Hrkach.